What is GCS
Reading File
Finding Sources
Searching PubMed
"Glasgow Coma Scale"
Searching the Web
Glasgow Coma Scale official scoring eyes verbal motor
GCS means Glasgow Coma Scale. It is a standardized bedside scale used to describe a person's level of consciousness, especially after head injury or in critical illness.
It records three responses:
| Component | Score range | What it assesses |
|---|---|---|
| Eye opening | 1-4 | Spontaneous or stimulus-induced eye opening |
| Verbal response | 1-5 | Orientation and ability to speak |
| Motor response | 1-6 | Ability to follow commands or respond to stimulation |
Total score = E + V + M, ranging from 3 to 15.
Common interpretation:
- 13-15: mild impairment
- 9-12: moderate impairment
- ≤8: severe impairment/coma. This level often signals the need to assess and protect the airway.
Scores should be documented by components, not only as a total. For example, E3 V4 M6 = GCS 13. This makes repeat assessments clearer. The scale uses assessment of eye opening, verbal response, and motor response as described by the official Glasgow Coma Scale resource.
For an intubated patient, verbal response cannot be tested and may be recorded as Vt or NT rather than assigning a misleading numerical verbal score.
Give detailed explanation of it
Reading File
Finding Sources
Searching PubMed
"Glasgow Coma Scale"
Searching the Web
Glasgow Coma Scale official structured assessment eye verbal motor scoring
Glasgow Coma Scale (GCS): detailed explanation
The Glasgow Coma Scale is a structured way to assess and communicate a person’s level of consciousness. It was developed for people with acute brain injury but is now widely used in emergency care, trauma, stroke, poisoning, infection, and intensive care.
It does not diagnose the cause of reduced consciousness. Instead, it describes how responsive the person is at that moment and helps clinicians detect improvement or deterioration over time.
The GCS assesses three observable responses:
- E: Eye opening, score 1 to 4
- V: Verbal response, score 1 to 5
- M: Motor response, score 1 to 6
The sum is from 3 to 15. The official approach emphasizes documenting the three individual components, not just the total, because two people with the same total can have very different clinical states. The official GCS guidance uses the same Eyes-Verbal-Motor structure.
1. Eye-opening response: E1 to E4
This measures arousal, not vision.
| Score | Response | Meaning |
|---|---|---|
| E4 | Eyes open spontaneously | Awake without stimulation |
| E3 | Opens eyes to sound or speech | Opens eyes when spoken to, for example when their name is called |
| E2 | Opens eyes to pressure | Opens eyes only after an appropriate central pressure stimulus |
| E1 | No eye opening | Does not open eyes even with stimulation |
Important points
- Do not score E4 simply because a person’s eyes are already open if they are asleep. Assess whether they open their eyes spontaneously when observed.
- Eyes may be unable to open because of facial injury, swelling, or eyelid disease. Record this as not testable, rather than falsely assigning E1.
- The updated terminology prefers “to pressure” rather than “to pain.” Pressure must be applied safely and only by trained clinical staff.
2. Verbal response: V1 to V5
This measures the quality of speech and orientation.
| Score | Response | Typical finding |
|---|---|---|
| V5 | Orientated | Correctly identifies who they are, where they are, and the approximate time/situation |
| V4 | Confused conversation | Talks in sentences but is disoriented or confused |
| V3 | Words | Recognizable single words or random speech, but no sustained conversation |
| V2 | Sounds | Moaning, groaning, or other incomprehensible sounds |
| V1 | No verbal response | No sound despite appropriate stimulation |
Example
A patient who says, “Leave me alone,” but believes they are at home when they are actually in hospital may score V4. They can converse, but are confused.
When verbal response cannot be assessed
Do not assign V1 merely because the patient cannot speak. Examples include:
- Endotracheal tube or tracheostomy
- Severe facial trauma
- Aphasia
- Language barrier
- Profound hearing impairment
Record the limitation explicitly, for example: E3 Vt M6, V-NT, or according to local documentation policy. The total score is not valid if a component is untestable.
3. Motor response: M1 to M6
This is usually the most clinically informative GCS component because it tests the ability to follow commands and the type of response to stimulation.
| Score | Response | Meaning |
|---|---|---|
| M6 | Obeys commands | Carries out a simple command, such as “show me two fingers” |
| M5 | Localizes pressure | Deliberately brings a hand toward the site of pressure to remove or stop it |
| M4 | Normal flexion | Pulls the limb away from stimulation, but does not reach toward the stimulus |
| M3 | Abnormal flexion | Stereotyped flexion posture, often called decorticate posturing |
| M2 | Extension | Stereotyped extension posture, often called decerebrate posturing |
| M1 | No motor response | No movement despite appropriate stimulation |
Localizing versus withdrawing: the key distinction
- M5, localizing: the person purposefully reaches toward the source of central stimulation, trying to push it away.
- M4, normal flexion/withdrawal: the limb pulls away but does not purposefully reach toward the stimulus.
This distinction can affect the score and therefore should be assessed carefully.
Abnormal posturing
- M3: abnormal flexion of arms, often with leg extension.
- M2: extension and internal rotation of arms, often with leg extension.
These are concerning signs of severe brain dysfunction, but they are not specific to one diagnosis.
Calculating and recording GCS
Add the components:
[
\text{GCS} = E + V + M
]
Example 1
- Opens eyes to speech: E3
- Confused conversation: V4
- Obeys commands: M6
GCS = 13/15, recorded as E3 V4 M6.
Example 2
- No eye opening: E1
- No verbal response: V1
- Normal flexion to pressure: M4
GCS = 6/15, recorded as E1 V1 M4.
Writing only “GCS 6” loses important information. E1 V1 M4 and E2 V2 M2 both total 6, yet represent different patterns of responsiveness.
Common clinical interpretation
For traumatic brain injury, GCS is often grouped as follows:
| Total GCS | Conventional category |
|---|---|
| 13-15 | Mild head injury |
| 9-12 | Moderate head injury |
| 3-8 | Severe head injury |
A GCS of 8 or below is often treated as a warning that the person may be unable to maintain or protect their airway. This is an assessment prompt, not an automatic rule that replaces clinical judgment.
More important than a single score is the trend. For example, a decline from E4 V5 M6 to E3 V4 M6 can signal neurological deterioration even though both values may seem relatively high.
How the assessment should be performed
A consistent sequence helps prevent inaccurate scores:
- Observe first for spontaneous eye opening, speech, movement, and posture.
- Speak clearly: call the person by name and give a simple command.
- If there is no adequate response, use appropriate stimulation according to trained clinical practice.
- Score the best response observed in each component.
- Record the components individually: for example, E2 V3 M5 = GCS 10.
- Note factors that interfere with assessment, such as sedation, paralysis, intubation, intoxication, language difficulties, or facial trauma.
- Repeat assessments using the same method and compare the trend.
The GCS was created to support repeated communication about responsiveness in acute brain injury, and standardized assessment improves consistency between observers, as described by the GCS structured assessment resource.
Limitations of GCS
GCS is useful but imperfect.
- Not a full neurological examination: pupils, limb strength, cranial nerves, breathing pattern, seizure activity, and vital signs must also be assessed.
- Affected by medications: sedatives, anesthetics, opioids, and neuromuscular blockers can lower the observed score.
- Affected by alcohol or drugs: intoxication may mimic or mask brain injury.
- Verbal score may be impossible to assess in intubation, aphasia, or facial trauma.
- Pediatric assessment differs: infants and preverbal children require an age-appropriate pediatric modification, especially for verbal response.
- A total score can conceal change: component scores and their trend are more meaningful than the sum alone.
Recent reviews also examine the prognostic value and limitations of GCS components, including the verbal component in traumatic brain injury (Pisano and Bilotta, 2024, PMID 38453630).
Quick memory aid
E4 V5 M6 = 15
-
Eyes: 4, 3, 2, 1
Spontaneous, speech, pressure, none -
Verbal: 5, 4, 3, 2, 1
Orientated, confused, words, sounds, none -
Motor: 6, 5, 4, 3, 2, 1
Obeys, localizes, normal flexion, abnormal flexion, extension, none
If this is for a real person who is hard to wake, newly confused, deteriorating, or has had a head injury, seek urgent medical evaluation or emergency care.
Symptoms and clinic features of Organophosphorus poisoning
Reading File
Finding Sources
Finding Sources
Searching PubMed
"Organophosphate Poisoning"
Searching the Web
organophosphate poisoning clinical features muscarinic nicotinic CNS symptoms authoritative
Reading File
Reading File
Reading Web Page
https://www.merckmanuals.com/professional/injuries-poisoning…
Organophosphorus (OP) poisoning: symptoms and clinical features
Organophosphorus compounds are commonly used in insecticides and include highly toxic nerve agents. They cause poisoning by inhibiting acetylcholinesterase, the enzyme that normally breaks down acetylcholine.
This produces excess acetylcholine at:
- Muscarinic receptors: glands, smooth muscle, heart, pupils
- Nicotinic receptors: autonomic ganglia and neuromuscular junctions
- Central nervous system (CNS)
The result is an acute cholinergic crisis, followed in some patients by delayed neurologic syndromes.
Emergency warning: suspected OP poisoning is a medical emergency, especially with excessive secretions, wheeze, weakness, drowsiness, or seizures. Remove the person from exposure without contaminating yourself, remove contaminated clothing if safe, and seek emergency/poison-center help immediately. Respiratory failure can develop rapidly.
1. Acute cholinergic syndrome
Symptoms usually begin within minutes to hours. Most symptomatic patients develop features within 8 hours and almost all within 24 hours, although onset can be delayed after skin exposure or with agents requiring metabolic activation.
A. Muscarinic features
A useful mnemonic is SLUDGE/DUMBELS.
| Feature | Clinical manifestation |
|---|---|
| Salivation | Profuse oral secretions, drooling |
| Lacrimation | Tearing |
| Urination | Urinary frequency or incontinence |
| Defecation/diarrhea | Loose stools, fecal incontinence |
| Gastrointestinal upset | Abdominal cramps, nausea, vomiting |
| Emesis | Vomiting |
| Miosis | Pinpoint pupils, blurred vision |
| Bronchorrhea | Copious airway secretions, “wet chest” |
| Bronchospasm | Wheeze, chest tightness, shortness of breath |
| Bradycardia | Slow pulse; hypotension may occur in severe poisoning |
| Sweating | Profuse diaphoresis |
The most dangerous muscarinic manifestations are bronchorrhea and bronchospasm. They can cause hypoxia and respiratory failure.
B. Nicotinic features
These occur at autonomic ganglia and neuromuscular junctions.
- Muscle twitching or fasciculations
- Muscle cramps
- Weakness, often progressing from proximal limb muscles
- Flaccid paralysis in severe poisoning
- Weakness of the diaphragm and intercostal muscles, causing respiratory failure
- Tachycardia and hypertension can occur, particularly early, because of autonomic ganglionic stimulation
A patient may therefore have both bradycardia from muscarinic effects and tachycardia from nicotinic effects, depending on timing and predominant receptor effects.
C. Central nervous system features
CNS effects range from agitation to coma:
- Headache, dizziness, fatigue
- Anxiety, restlessness, irritability
- Tremor
- Confusion, disorientation, slurred speech
- Ataxia or impaired gait
- Drowsiness, lethargy
- Seizures, particularly in severe poisoning and in children
- Coma
- Central respiratory depression
The CDC toxicology guidance describes CNS effects including confusion, impaired coordination, convulsions, loss of consciousness, coma, and respiratory depression.
2. Respiratory features
Respiratory failure is the principal cause of death. It can result from several processes occurring together:
- Bronchorrhea: airways fill with secretions
- Bronchospasm: narrowed airways causing wheeze and increased work of breathing
- Weakness/paralysis: respiratory muscles fail because of nicotinic toxicity
- CNS depression: reduced respiratory drive
- Aspiration: vomiting or reduced consciousness may lead to aspiration pneumonitis
Clinical signs include:
- Breathlessness or tachypnea
- Wheeze and coarse crackles/rhonchi
- Cyanosis or low oxygen saturation
- Use of accessory respiratory muscles
- Weak cough and inability to clear secretions
- Progressive exhaustion, apnea, or respiratory arrest
3. Characteristic examination findings
A typical severe OP-poisoned patient may appear:
- Wet: salivation, tearing, sweating, bronchial secretions
- Pinpoint pupils
- Wheezy and hypoxic
- Bradycardic and hypotensive
- Fasciculating and weak
- Confused, drowsy, or comatose
A high-yield pattern is:
Miosis + profuse secretions + wheeze/bronchorrhea + fasciculations/weakness
This strongly suggests a cholinergic toxidrome in the appropriate exposure setting. The Merck Manual review lists salivation, lacrimation, diarrhea, vomiting, miosis, bronchorrhea, wheezing, bradycardia, fasciculations, and weakness as key acute features.
4. Other possible features and complications
- Bradyarrhythmias, heart block, hypotension
- Tachyarrhythmias and QT-interval prolongation
- Pulmonary edema
- Aspiration pneumonia or chemical pneumonitis, particularly if the formulation contains hydrocarbon solvents
- Pancreatitis
- Hyperglycemia and electrolyte abnormalities
- Rhabdomyolysis in severe cases
- Acute kidney injury secondary to shock, hypoxia, or rhabdomyolysis
5. Intermediate syndrome
This occurs about 1 to 4 days after the acute cholinergic crisis, sometimes after the patient initially appears better.
Features
- Weakness of neck flexors and proximal limb muscles
- Cranial nerve weakness: facial weakness, dysphagia, dysarthria
- Respiratory muscle weakness
- Reduced reflexes
- Respiratory failure requiring ventilatory support
Unlike the early phase, prominent secretions and miosis may be less obvious. The main concern is neuromuscular respiratory failure. The Merck Manual describes proximal, cranial, and respiratory muscle weakness developing 1 to 3 days after exposure.
6. Organophosphate-induced delayed neuropathy
A delayed neuropathy may occur 1 to 3 weeks after exposure with certain OP compounds.
Features
- Tingling or burning sensations in the feet and legs
- Distal muscle weakness, often beginning in lower limbs
- Foot drop
- Gait difficulty
- Reduced reflexes
- Sensory-motor polyneuropathy
Recovery may be incomplete in severe cases.
7. Chronic or long-term effects
Some survivors may have persistent symptoms, especially after severe poisoning:
- Fatigue and weakness
- Memory difficulty and impaired concentration
- Irritability, anxiety, depression
- Sleep disturbance
- Persistent peripheral neuropathy
- Rarely, parkinsonian features
These longer-term effects are variable and should not be confused with the immediate cholinergic crisis.
Summary table
| System | Main findings |
|---|---|
| Eyes | Miosis, blurred vision, lacrimation |
| Glands/skin | Salivation, sweating, bronchial secretions |
| Respiratory | Bronchorrhea, bronchospasm, wheeze, hypoxia, respiratory muscle weakness |
| Gastrointestinal | Nausea, vomiting, diarrhea, abdominal cramps |
| Genitourinary | Urination/incontinence |
| Cardiovascular | Bradycardia, hypotension, sometimes tachycardia/hypertension, arrhythmias |
| Neuromuscular | Fasciculations, cramps, weakness, paralysis |
| CNS | Agitation, confusion, seizures, coma, respiratory depression |
| Delayed | Intermediate syndrome, then possible delayed peripheral neuropathy |
Recent evidence reviews on OP poisoning focus mainly on treatment rather than changing this established clinical pattern, including a 2026 umbrella review (PMID 42258859).
This is a shared conversation. Sign in to Orris to start your own chat.